soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

🔴Notable Articles of 2024 ⤵️@NEJM 1. FLOW trial-Semaglutide into mainstream 🧑‍⚖️Semaglutide ⬇️reduced risks of kidney outcomes and death from CVS cause in pts with T2DM and CKD 2❣️FINEARTS-HF-MRAs in Heart Failure 🧑‍⚖️

28.30

★★★★☆4.8 (126)

Oral semaglutide found to lower risk of heart failure events in people with type 2 diabetes

26.26

★★★★★4.9 (98)

NEJM Editorial Fellow Harleen Marwah, MD, summarizes the SOUL trial. Read the full trial results at NEJM.org (link in bio). ⁣, ⁣, #ACC25 #Cardiology #ClinicalTrials #NEJM

23.02

★★★★★5.0 (157)

Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial

27.96

★★★★★4.7 (84)

🔴Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants

22.78

★★★★★4.9 (203)

GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and #obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read

24.04

★★★★★5.0 (176)

An oral formulation of semaglutide lowered the risk major adverse cardiovascular events by 14% in four years, with no change in safety profile compared to placebo, according to the SOUL study. #ACC25

20.29

★★★★★4.8 (132)